Phaseline

Targets › B6N

B6N: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jan 2030.

Open in Phaseline: the race on B6N, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PfizerPF-08052667
Anti-B6N antibody-drug conjugate
B6NPhase 1Non-muscle Invasive Bladder CancerJan 2030

Conditions

Non-muscle Invasive Bladder Cancer (1)

Modalities

mixed (1)

Companies

Pfizer (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.